About Penta
Who we are
Our Strategy
Our Network
Working Groups
Penta Foundation
Our Staff
Diversity and Inclusion
Annual reports
Our Activities
News & Webinars
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Calls for service
PentaTr@ining
Archivio
Pharmacokinetics (PK) of Nelfinavir (NFV) and its Active Metabolite (M8) in Very Young Infants Infected with Human Immunodeficiency Virus (HIV)
Evolution of drug resistance in antiretroviral therapy-naïve children in PENTA 5
T cell repopulation in HIV infected children on highly active anti-retroviral therapy (HAART)
Evaluation of Toxicity, Tolerability and Antiviral Activity of Early d4T+ddI+Nelfinavir (NFV) Therapy in HIV-1 Vertically Infected Infants : 24 Week Preliminary Results from the PENTA 7 Study